Clene Nanomedicine

This company profile has not been updated since December 2020, when Clene Nanomedicine merged with Tottenham Acquisition I to form Clene.Clene Nanomedicine is a subsidiary of Clene Inc was focused on developing nanotherapeutic medicines for the treatment of bioenergetic failure associated with neurodegenerative diseases. Clene created a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs.In September 2021, Tottenham Acquisition I Limited announced that it has entered into a definitive merger agreement for a business combination with Clene Nanomedicine, Inc.In August 2021, Clene, Inc and Clene Nanomedicine, Inc announced the completion of two lease agreements.In September 2020, Tottenham Acquisition I entered into a definitive merger agreement with Clene Nanomedicine. Tottenham would reincorporate to the state of Delaware by merging with and into Chelsea Worldwide, a Delaware company and wholly owned subsidiary of